Photo by markusspiske from unsplash
Treatment of patients with Haemophilia A has improved significantly in recent years since the advent of novel therapeutic agents such as emicizumab. The low annualised bleeding rates associated with emicizumab… Click to show full abstract
Treatment of patients with Haemophilia A has improved significantly in recent years since the advent of novel therapeutic agents such as emicizumab. The low annualised bleeding rates associated with emicizumab have liberated many patients from the need for central venous access devices (CVAD). Optimal peri‐operative management of CVAD removal is not currently known and there are no specific formal recommendations available.
Keywords:
emicizumab prophylaxis;
receiving emicizumab;
removal;
removal patients;
port removal;
patients receiving
Journal Title: Haemophilia
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haemophilia
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!